Ambitious Expansion: PharmEasy Aims for Rs 3,500 Crore Investment Through Right Issue
Amidst the current challenging market conditions, API Holdings Limited, the parent company of the prominent online pharmacy platform PharmEasy, has revealed its intention to raise approximately Rs 3,500 crore through a rights issue. The funds will be sought from its existing backers, signaling the company’s strategic move to secure additional capital during this period.
The decision to raise capital through a rights issue, which involves offering existing shareholders the opportunity to purchase additional shares at a predetermined price, reflects API Holdings’ efforts to bolster its financial position and navigate the evolving dynamics of the market. The funds raised through this initiative will likely be allocated towards further expanding its operations, enhancing its technological infrastructure, and driving growth within the competitive pharmaceutical and e-commerce landscape.
A notable lineup of investors, including Temasek, TPG Growth, Prosus Ventures, CDPQ, Eight Roads Ventures, LGT Lightstone, ADQ (Abu Dhabi’s sovereign wealth fund), Amansa, OrbiMed, and Sunil Kant Munjal’s family office, have shown keen interest in investing up to Rs 2,000 crore in API Holdings Limited. This group of esteemed investors signifies the confidence and recognition the company has garnered within the investment community.
Their willingness to contribute substantial capital underscores the attractiveness of API Holdings and its subsidiary PharmEasy, particularly in the healthcare and e-commerce sectors. This infusion of funds could significantly boost the company’s financial resources, enabling it to execute strategic plans, expand its footprint, and innovate its services to cater to evolving consumer demands. The involvement of such a diverse and reputable consortium of investors could further validate API Holdings’ position as a key player in the digital healthcare ecosystem.
Ranjan Pai’s family office is reportedly considering an investment of Rs 1,200 crore in API Holdings Limited, as per a report by Mint. This potential investment comes at a time when the company is planning to raise funds through a right issue from existing backers. The influx of funds from Pai’s family office and other investors could play a crucial role in addressing financial obligations, including the repayment of a term loan obtained from Goldman Sachs.
Earlier reports suggested that PharmEasy, a subsidiary of API Holdings, had encountered challenges related to loan covenant terms with Goldman Sachs, possibly leading to breaches. The new financing round could provide the necessary capital to rectify these issues and strengthen the company’s financial position. By repaying its loans and resolving financial concerns, API Holdings might be better positioned to focus on its growth strategies and expansion plans in the competitive healthcare sector.
PharmEasy, a prominent player in the online pharmacy space, has experienced significant adjustments in its valuation this year. Backers and investors, including Neuberger Berman and Janus Henderson, have reportedly reduced the company’s valuation by around 50% collectively. These valuation adjustments reflect the evolving market dynamics and investor sentiment within the healthcare and e-commerce sectors.
In February, Neuberger Berman marked down PharmEasy’s valuation by approximately 21.4%, valuing the company at $4.4 billion. This reduction could be attributed to a combination of factors, including changing market conditions, competitive pressures, and the company’s financial performance. Subsequently, Janus Henderson further adjusted the valuation downward to $2.8 billion, signifying a more substantial decrease in the company’s perceived worth.
These valuation adjustments underscore the challenges that PharmEasy and its parent company API Holdings are navigating amidst the evolving landscape of online healthcare services. As the company seeks to raise funds through a right issue and secure investments from existing backers, addressing these valuation changes could be a crucial aspect of attracting capital and fostering investor confidence in the company’s growth prospects.
The potential valuation range of $500 million (pre-money) for PharmEasy’s upcoming round signals a substantial erosion of the company’s value compared to its peak valuation of $5.6 billion in October 2021. This sharp decline of approximately 90% underscores the challenges and shifts in the dynamics of the online pharmacy sector over the past year.
Several factors might have contributed to this significant valuation drop. Regulatory changes, intensified competition, and evolving consumer behavior could have played a role in reshaping the market landscape. Additionally, concerns about profitability, operational efficiency, and the overall financial performance of PharmEasy may have influenced investor sentiment and contributed to the lowered valuations.
While the current market conditions pose challenges for the company, the infusion of capital through the right issue and investments from existing backers could provide PharmEasy with the necessary resources to address these challenges, strengthen its position in the market, and potentially regain investor confidence.
PharmEasy’s decision to postpone its IPO plans in August 2022 reflects the cautious approach adopted by the company in light of the challenging market conditions prevailing at that time. The postponement might have been influenced by factors such as market volatility, investor sentiment, and broader economic uncertainties.
The growth in the company’s scale, reaching Rs 5,729 crore during FY22, signifies its expansion efforts within the online pharmacy sector. This substantial increase of 2.5 times in scale reflects PharmEasy’s commitment to capturing a larger market share and serving a broader customer base.
However, the significant increase in losses, rising by 4.3 times to Rs 3,992 crore during the same period, underscores the financial challenges and the competitive landscape faced by the company. Addressing these losses and achieving profitability could be key areas of focus for PharmEasy moving forward.
Despite the challenges and the valuation adjustments, PharmEasy’s potential Rs 3,500 crore right issue with the participation of existing backers could provide a fresh infusion of capital that the company can deploy strategically to strengthen its operations, enhance efficiency, and navigate the evolving dynamics of the online pharmacy industry.
